thomasdevos
10-05-2009, 09:57 PM
Everything You Need To Know About Drugs Prostate Cancer
Drugs against prostate cancer in conjunction with hormone use an aggressive treatment against the progression of prostate cancer. Wonder why? Well, men produce a hormone known as testosterone, often likened to a guy macho, testosterone can stimulate the growth of cancer cells in the prostate, in turn accelerate the development of cancer prostate. This is where hormonal therapy comes in. Otherwise known as androgen deprivation, the supply cuts off hormone therapy for prostate of testosterone. Treatment with hormones is usually a route taken by patients whose cancer has become metastatic, or left of the prostate and spread to other parts of the body.
The testes are encouraged to produce a form of cancer potentially induct testosterone by a chemical called internal LHRH, or luteinizing hormone-releasing hormone. Luteinizing hormone-releasing analogs and luteinizing hormone-releasing antagonists for prostate cancer are drugs designed to inhibit the release of LHRH from the brain, resulting in lower levels of testosterone in influencing non cancerous prostate cells.
Luteinizing Hormone-Releasing Analogs
Luteinizing-releasing hormone analogues are designed to lower testosterone levels. These drugs against prostate cancer are administered by injection can be administered monthly or every three, six or nine months. Most patients with metastases of prostate cancer opt for that course of treatment of prostate cancer in a surgical removal of their testes, although side effects may be the same.
Luteinizing-Releasing Hormone Antagonists
There is a new antagonist of the city. Plenaxis characteristics of the new age of LHRH antagonist and has been cited to reduce testosterone at the speed of light (well, almost) and does not cause a surge in testosterone levels before taking affect, as is the case with LHRH analogues. However, LHRH antagonists can be used in men who are not able to use other forms of hormonal treatment. Abarelix is another LHRH antagonist, but it is given to a small group physican's office. Other municipalities are LHRH antagonists Lupron, Zoladex, Eulexin and Casodex.
Anti-androgens
In addition to LHRH analogues and antagonists, tap other anti-androgens are drugs for prostate cancer. Androgens, like testosterone, may still be produced in trace amounts after surgical removal of the testicles or a cycle of treatment with LHRH analogues. In an effort to block any stray androgens, the anti-androgen for prostate cancer provide a complete blockage of hormones. Anti-androgens have been linked to produce fewer problems with sexual dysfunction than other types of hormonal drugs for prostate cancer. The downside, antiandrogens have developed a reputation for side effects such as diarrhea, liver problems, and fatigue.
Clinical Trials
Clinical trials may provide a powerful impact against the prostate cancer progression. More tests are part of a journey that all drugs against prostate cancer should take. Clinical trials for prostate cancer drugs go through three phases:
<li> Phase I: The first phase of clinical trials testing the safety of new drug </li>
<li> Phase II: Phase II is to see if and how this new drug. Patients receiving high doses of the drug being tested only in the level of security. Patients are then looked to see the effect of the drug tested on their prostate cancer. </li>
<li> Phase III: The final phase of clinical trials on drugs trial rivals test with standard treatments. A control group was given doses of the drug being tested while a second group continued with standard methods of medicine. The results of the two treatments are then monitored closely. </li>
Reference Site:
prostate cancer treatment (http://prostate-cancer-treatment-cure.com)
prostatecancerfoundation (http://www.prostatecancerfoundation.org)
en.wikipedia.org (http://en.wikipedia.org/wiki/Prostate_cancer)
www.cancer.gov (http://www.cancer.gov/cancertopics/types/prostate)
neworiental (http://www.neworiental.org/publish/portal0/tab1127/info377702.htm)
Drugs against prostate cancer in conjunction with hormone use an aggressive treatment against the progression of prostate cancer. Wonder why? Well, men produce a hormone known as testosterone, often likened to a guy macho, testosterone can stimulate the growth of cancer cells in the prostate, in turn accelerate the development of cancer prostate. This is where hormonal therapy comes in. Otherwise known as androgen deprivation, the supply cuts off hormone therapy for prostate of testosterone. Treatment with hormones is usually a route taken by patients whose cancer has become metastatic, or left of the prostate and spread to other parts of the body.
The testes are encouraged to produce a form of cancer potentially induct testosterone by a chemical called internal LHRH, or luteinizing hormone-releasing hormone. Luteinizing hormone-releasing analogs and luteinizing hormone-releasing antagonists for prostate cancer are drugs designed to inhibit the release of LHRH from the brain, resulting in lower levels of testosterone in influencing non cancerous prostate cells.
Luteinizing Hormone-Releasing Analogs
Luteinizing-releasing hormone analogues are designed to lower testosterone levels. These drugs against prostate cancer are administered by injection can be administered monthly or every three, six or nine months. Most patients with metastases of prostate cancer opt for that course of treatment of prostate cancer in a surgical removal of their testes, although side effects may be the same.
Luteinizing-Releasing Hormone Antagonists
There is a new antagonist of the city. Plenaxis characteristics of the new age of LHRH antagonist and has been cited to reduce testosterone at the speed of light (well, almost) and does not cause a surge in testosterone levels before taking affect, as is the case with LHRH analogues. However, LHRH antagonists can be used in men who are not able to use other forms of hormonal treatment. Abarelix is another LHRH antagonist, but it is given to a small group physican's office. Other municipalities are LHRH antagonists Lupron, Zoladex, Eulexin and Casodex.
Anti-androgens
In addition to LHRH analogues and antagonists, tap other anti-androgens are drugs for prostate cancer. Androgens, like testosterone, may still be produced in trace amounts after surgical removal of the testicles or a cycle of treatment with LHRH analogues. In an effort to block any stray androgens, the anti-androgen for prostate cancer provide a complete blockage of hormones. Anti-androgens have been linked to produce fewer problems with sexual dysfunction than other types of hormonal drugs for prostate cancer. The downside, antiandrogens have developed a reputation for side effects such as diarrhea, liver problems, and fatigue.
Clinical Trials
Clinical trials may provide a powerful impact against the prostate cancer progression. More tests are part of a journey that all drugs against prostate cancer should take. Clinical trials for prostate cancer drugs go through three phases:
<li> Phase I: The first phase of clinical trials testing the safety of new drug </li>
<li> Phase II: Phase II is to see if and how this new drug. Patients receiving high doses of the drug being tested only in the level of security. Patients are then looked to see the effect of the drug tested on their prostate cancer. </li>
<li> Phase III: The final phase of clinical trials on drugs trial rivals test with standard treatments. A control group was given doses of the drug being tested while a second group continued with standard methods of medicine. The results of the two treatments are then monitored closely. </li>
Reference Site:
prostate cancer treatment (http://prostate-cancer-treatment-cure.com)
prostatecancerfoundation (http://www.prostatecancerfoundation.org)
en.wikipedia.org (http://en.wikipedia.org/wiki/Prostate_cancer)
www.cancer.gov (http://www.cancer.gov/cancertopics/types/prostate)
neworiental (http://www.neworiental.org/publish/portal0/tab1127/info377702.htm)